StemCell United Limited (ASX: SCU) revealed that it has secured a contract to supply 50 tonnes of Daemonorops Draco Blume extract (Resina) to the Chinese customer in the next 5 years. Of which, the company has delivered an initial 1 tonne of Resina to Zhejiang Forest Rainbow Medical Co Ltd under the contract. As per the terms of the Contract, the agreed price of Resina was decided at US$200 per kg (or US$200,000 per tonne) but it is subject to market price changes. It is expected that Group will generate a profit of about US$40,000 per tonne. In addition to this, SCU will be involved in the supply chain management and quality check as per China’s import regulations and safety standards. Following this, the company procured the Resina Powder from its agents and ships it to the subcontractors for extraction purpose of its active agents i.e., Dracohodin, and then process this powder to cakes form. On the development site, the first shipment has been released to the Chinese company on July 09, 2018. With the announcement, the share price climbed up 24 per cent on July 13, 2018 with the intra-day trading volume of more than 47.5 Mn before market close.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.